2. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. *(Withdrawn)* A method of treating cardiovascular disease in a subject having cardiovascular disease, the method comprising administering to the subject a therapeutically effective amount of an antagonist, wherein the antagonist is selected from the group consisting of an IL-17 antagonist, IL-18 antagonist, 4-1BB antagonist, CD30 antagonist and an OX40 antagonist.

2. *(Withdrawn)* The method of Claim 1, wherein the IL-17 antagonist is a soluble IL-17 receptor.

3. *(Withdrawn)* The method of Claim 2, wherein the soluble IL-17 receptor is a fusion protein.

4. *(Withdrawn)* The method of Claim 1, wherein the IL-17 antagonist is an antibody.

5. *(Withdrawn)* The method of Claim 4, wherein the antibody specifically binds the IL-17 receptor.

6. *(Withdrawn)* The method of Claim 4, wherein the antibody specifically binds IL-17.

7. *(Withdrawn)* The method of Claim 4, wherein the antibody is a humanized antibody.

8. *(Withdrawn)* The method of Claim 4, wherein the antibody is a single-chain antibody.

9. *(Withdrawn)* The method of Claim 1, wherein the IL-17 antagonist is administered one or more times per week.

10. *(Withdrawn)* The method of Claim 1, wherein the IL-17 antagonist is administered by subcutaneous injection.

11. *(Withdrawn)* The method of Claim 1, wherein the IL-17 antagonist is administered in combination with one or more compounds selected from the group consisting of non-steroidal anti-inflammatory drugs; analgesics; systemic steroids; antagonists of inflammatory cytokines; anti-inflammatory cytokines; chemotherapeutics; lipid-lowering drugs; blood pressure-regulating drugs; angiotensin-converting enzyme inhibitors and/or peroxisome proliferator-activated receptor ligands.

12. *(New)* A method of treating cardiovascular disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a 4-1BB antagonist.

13. *(New)* The method of Claim 12, wherein the 4-1BB antagonist is a soluble 4-1BB Ligand protein.

14. *(New)* The method of Claim 13, wherein the soluble 4-1BB Ligand is an Fc fusion protein.

15. *(New)* The method of Claim 12, wherein the 4-1BB antagonist is a 4-1BB-specific antibody.

16. *(New)* The method of Claim 15, wherein the antibody specifically binds the extracellular domain of 4-1BB Ligand.

17. *(New)* The method of Claim 15, wherein the antibody is a humanized antibody.

18. *(New)* The method of Claim 15, wherein the antibody is a human antibody.

19. *(New)* The method of Claim 15, wherein the antibody is a single-chain antibody.

20. *(New)* The method of Claim 12, wherein the 4-1BB antagonist is administered by subcutaneous injection.

21. *(New)* The method of Claim 12, wherein the 4-1BB antagonist is administered in combination with one or more compounds selected from the group consisting of non-steroidal anti-inflammatory drugs; analgesics; systemic

steroids; antagonists of inflammatory cytokines; anti-inflammatory cytokines; chemotherapeutics; lipid-lowering drugs; blood pressure-regulating drugs; angiotensin-converting enzyme inhibitors and/or peroxisome proliferator-activated receptor ligands.

22. *(New)* A method for preventing, reducing and/or ameliorating the cardiotoxic side effects of one or more chemotherapeutics in subjects receiving said chemotherapeutics, comprising administering a 4-1BB antagonist to the subject.

23. *(New)* The method according to Claim 22, wherein the chemotherapeutic is an anthracycline.

24. *(New)* The method according to Claim 23, wherein the anthracylcine is selected from the group consisting of Doxorubicin, Daunorubicin, Epirubicin, Idarubicin and Mitroxantrone.

25. *(New)* The method according to Claim 22, comprising administering a 4-1BB antagonist prior to, concurrent with and/or subsequent to the one or more anthracyclines.

26. *(New)* The method according to Claim 22, wherein the one or more cardiotoxic side effects is/are selected from the group consisting of arrythmias, myocarditis, pericarditis, myocardial infarction and cardiomyopathy.

27. *(New)* A method for treating cancer in a subject in need thereof, comprising administering one or more anthracyclines in combination with a 4-1BB antagonist, wherein the 4-1BB antagonist is administered prior to, concurrent with and/or subsequent to the anthracyclines.

28. *(New)* The method according to Claim 27, wherein the dosage of the anthracycline is increased to more effectively treat the cancer but the cardiotoxic side effects of the anthracycline is prevented, reduced and/or ameliorated by administering a 4-1BB antagonist.

29. *(New)* A method for reducing or preventing apoptosis in cardiac tissue comprising administering a 4-1BB antagonist.

30. *(New)* A method for improving cardiac function in subjects having anthracycline-induced cardiac deficiency comprising administering a 4-1BB antagonist prior to, concurrent with and/or subsequent to the anthracycline.